QUINOLONES AND THEIR THERAPEUTIC USE

A compound of formula (I), wherein R1 represents a bicyclic structure in which a cycloalkyl or heterocyclo ring is bound to NH and is fused to a second ring selected from aryl or heteroaryl, and in which either or each ring is optionally substituted by one or more substituents chosen from halo, C1-6...

Full description

Saved in:
Bibliographic Details
Main Authors HAUGHAN, ALAN FINDLAY, MONTANA, JOHN GARY, RUNCIE, KAREN ANN, BEASLEY, STEVEN COLIN, WATSON, ROBERT JOHN
Format Patent
LanguageEnglish
French
Published 28.08.1997
Edition6
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A compound of formula (I), wherein R1 represents a bicyclic structure in which a cycloalkyl or heterocyclo ring is bound to NH and is fused to a second ring selected from aryl or heteroaryl, and in which either or each ring is optionally substituted by one or more substituents chosen from halo, C1-6 alkoxy, hydroxy, CN, CO2H (or C1-6 alkyl esters or C1-6 alkyl amides thereof), C1-6 alkyl, NR6R7 and SO2NR6R7; R3, R4 and R5 are the same or different and represent H, halo, C1-6 alkoxy, hydroxy, CN, CO2H (or C1-6 alkyl esters or C16 alkyl amides thereof), NR6R7, SO2NR6R7 or C1-6 alkyl in which alkyl is optionally substituted with halo, C1-6 alkoxy, hydroxy, CN, CO2H (or C1-6 alkyl esters or C1-6 alkyl amides thereof), NR6R7 or SO2NR6R7, or any adjacent two substituents R3-R5 are joined to form an optionally substituted carbocyclic aromatic, heteroaromatic, saturated carbocyclic or heterocyclic ring; R6 and R7 are the same or different and represent H, C1-6 alkyl, cycloalkyl, C1-6 alkylcarbonyl, arylcarbonyl, C1-6 alkoxycarbonyl, arylsulphonyl or C1-6 alkylsulphonyl, or NR6R7 is a 5 or 6-membered ring such as pyrrolidine, piperidine, morpholine or piperazine; X represents a linking group selected from -(CR9R10)2-3-, -Y-(CR9R10)2-, -(CR9R10)2-Y-, -CR9R10-Y-CR9R10- and -Y-CR9R10-Z-, Y and Z being independently NR11, O or S(O)0-2, provided that Y and Z are not both S(O)0-2; Q represents O or S; and each R9, each R10 and R11 are the same or different and are H or C1-6 alkyl; or a pharmaceutically-acceptable salt, solvate or hydrate thereof.
Bibliography:Application Number: CA19972242598